LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: Headguard use in combat sports: position statement of the Association of Ringside Physicians.

    deWeber, Kevin / Parlee, Lindsay / Nguyen, Alexander / Lenihan, Michael W / Goedecke, Leah

    The Physician and sportsmedicine

    2023  , Page(s) 1–10

    Abstract: Headguard use is appropriate during some combat sports activities where the risks of injury to the face and ears are elevated. Headguards are highly effective in reducing the incidence of facial lacerations in studies of amateur boxers and are just as ... ...

    Abstract Headguard use is appropriate during some combat sports activities where the risks of injury to the face and ears are elevated. Headguards are highly effective in reducing the incidence of facial lacerations in studies of amateur boxers and are just as effective in other striking sports. They should be used in scenarios - especially sparring prior to competitions - where avoidance of laceration and subsequent exposure to potential blood-borne pathogens is important. Headguards are appropriate where avoidance of auricular injury is deemed important; limited data show a marked reduction in incidence of auricular injury in wrestlers wearing headguards.Headguards should not be relied upon to reduce the risk of concussion or other traumatic brain injury. They have not been shown to prevent these types of injuries in combat sports or other sports, and human studies on the effect of headguards on concussive injury are lacking. While biomechanical studies suggest they reduce linear and rotational acceleration of the cranium, changes in athlete behavior to more risk-taking when wearing headguards may offset any risk reduction. In the absence of high-quality studies on headguard use, the Association of Ringside Physicians recommends that further research be conducted to clarify the role of headguards in all combat sports, at all ages of participation. Furthermore, in the absence of data on gender differences, policies should be standardized for men and women.
    Language English
    Publishing date 2023-08-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 753046-8
    ISSN 2326-3660 ; 0091-3847
    ISSN (online) 2326-3660
    ISSN 0091-3847
    DOI 10.1080/00913847.2023.2242415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.

    Tavee, Jinny / Brannagan, Thomas H / Lenihan, Michael W / Muppidi, Sri / Kellermeyer, Liz / D Donofrio, Peter

    Muscle & nerve

    2023  Volume 68, Issue 4, Page(s) 356–374

    Abstract: Intravenous immune globulin (IVIG) is an immune-modulating biologic therapy that is increasingly being used in neuromuscular disorders despite the paucity of high-quality evidence for various specific diseases. To address this, the AANEM created the 2009 ...

    Abstract Intravenous immune globulin (IVIG) is an immune-modulating biologic therapy that is increasingly being used in neuromuscular disorders despite the paucity of high-quality evidence for various specific diseases. To address this, the AANEM created the 2009 consensus statement to provide guidance on the use of IVIG in neuromuscular disorders. Since then, there have been several randomized controlled trials for IVIG, a new FDA-approved indication for dermatomyositis and a revised classification system for myositis, prompting the AANEM to convene an ad hoc panel to update the existing guidelines.New recommendations based on an updated systemic review of the literature were categorized as Class I-IV. Based on Class I evidence, IVIG is recommended in the treatment of chronic inflammatory demyelinating polyneuropathy, Guillain-Barré Syndrome (GBS) in adults, multifocal motor neuropathy, dermatomyositis, stiff-person syndrome and myasthenia gravis exacerbations but not stable disease. Based on Class II evidence, IVIG is also recommended for Lambert-Eaton myasthenic syndrome and pediatric GBS. In contrast, based on Class I evidence, IVIG is not recommended for inclusion body myositis, post-polio syndrome, IgM paraproteinemic neuropathy and small fiber neuropathy that is idiopathic or associated with tri-sulfated heparin disaccharide or fibroblast growth factor receptor-3 autoantibodies. Although only Class IV evidence exists for IVIG use in necrotizing autoimmune myopathy, it should be considered for anti-hydroxy-3-methyl-glutaryl-coenzyme A reductase myositis given the risk of long-term disability. Insufficient evidence exists for the use of IVIG in Miller-Fisher syndrome, IgG and IgA paraproteinemic neuropathy, autonomic neuropathy, chronic autoimmune neuropathy, polymyositis, idiopathic brachial plexopathy and diabetic lumbosacral radiculoplexopathy.
    MeSH term(s) Humans ; Child ; Immunoglobulins, Intravenous/therapeutic use ; Dermatomyositis ; Neuromuscular Diseases/therapy ; Myasthenia Gravis/therapy ; Guillain-Barre Syndrome ; Myositis ; Polyneuropathies ; Myositis, Inclusion Body
    Chemical Substances Immunoglobulins, Intravenous
    Language English
    Publishing date 2023-07-11
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 438353-9
    ISSN 1097-4598 ; 0148-639X
    ISSN (online) 1097-4598
    ISSN 0148-639X
    DOI 10.1002/mus.27922
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The clinical presentation of chronic traumatic encephalopathy.

    Lenihan, Michael W / Jordan, Barry D

    Current neurology and neuroscience reports

    2015  Volume 15, Issue 5, Page(s) 23

    Abstract: Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder attributed to repetitive mild traumatic brain injury. The diagnosis in a living individual can be challenging and can be made definitively only at autopsy. The symptoms ... ...

    Abstract Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder attributed to repetitive mild traumatic brain injury. The diagnosis in a living individual can be challenging and can be made definitively only at autopsy. The symptoms are often nonspecific and overlap with neurodegenerative disorders such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). Higher exposure to repetitive head trauma increases the risk of CTE. Genetic risk factors such as presence of an apolipoprotein E ε4 allele may be important. Individuals have varying degrees of cognitive, behavioral, and motor decline. Limitations in the manner in which data have been obtained over the years have led to different clinical descriptions of CTE. At present, there are no biomarkers to assist in the diagnosis. Standard neuroimaging may show nonspecific atrophic changes; however, newer imaging modalities such as positron emission tomography (PET) and diffusion tensor imaging (DTI) show promise. Neuropsychological testing may be helpful in determining the pattern of cognitive or behavioral decline.
    MeSH term(s) Brain Injuries/diagnosis ; Brain Injuries/therapy ; Chronic Disease ; Humans ; Neuroimaging
    Language English
    Publishing date 2015-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2057363-7
    ISSN 1534-6293 ; 1528-4042
    ISSN (online) 1534-6293
    ISSN 1528-4042
    DOI 10.1007/s11910-015-0541-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: How to Manage Patients With Cardiac Implantable Electronic Devices Undergoing Radiation Therapy.

    Fradley, Michael G / Lefebvre, Bénédicte / Carver, Joseph / Cheung, Jim W / Feigenberg, Steven J / Lampert, Rachel / Liu, Jennifer / Rajagopalan, Bharath / Lenihan, Daniel J

    JACC. CardioOncology

    2021  Volume 3, Issue 3, Page(s) 447–451

    Language English
    Publishing date 2021-09-21
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2666-0873
    ISSN (online) 2666-0873
    DOI 10.1016/j.jaccao.2021.08.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Cardiac Biomarkers During Cancer Therapy: Practical Applications for Cardio-Oncology.

    Alvarez-Cardona, Jose A / Zhang, Kathleen W / Mitchell, Joshua D / Zaha, Vlad G / Fisch, Michael J / Lenihan, Daniel J

    JACC. CardioOncology

    2020  Volume 2, Issue 5, Page(s) 791–794

    Language English
    Publishing date 2020-12-15
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2666-0873
    ISSN (online) 2666-0873
    DOI 10.1016/j.jaccao.2020.08.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).

    Zhang, Kathleen W / Reimers, Melissa A / Calaway, Adam Christopher / Fradley, Michael G / Ponsky, Lee / Garcia, Jorge A / Cullen, Jennifer / Baumann, Brian C / Addison, Daniel / Campbell, Courtney M / Ghosh, Arjun K / Lenihan, Daniel J / Desai, Nihar R / Weintraub, Neal / Guha, Avirup

    The Journal of urology

    2021  Volume 206, Issue 3, Page(s) 613–622

    Abstract: Purpose: The comparative cardiovascular risk profiles of available hormone therapies for the treatment of prostate cancer is not known.: Materials and methods: We queried the U.S. Food and Drug Administration Adverse Event Reporting System, a ... ...

    Abstract Purpose: The comparative cardiovascular risk profiles of available hormone therapies for the treatment of prostate cancer is not known.
    Materials and methods: We queried the U.S. Food and Drug Administration Adverse Event Reporting System, a retrospective, pharmacovigilance database, for cardiovascular adverse event reports in men with prostate cancer receiving gonadotropin releasing hormone (GnRH) agonists, GnRH antagonists, androgen receptor antagonists, and/or androgen synthesis inhibitors from January 2000 to April 2020.
    Results: Cardiovascular adverse events accounted for 6,231 reports (12.6%) on hormone monotherapy and 1,793 reports (26.1%) on combination therapy. Arterial vascular events were reported most commonly, followed by arrhythmias, heart failure, and venous thromboembolism. Compared to GnRH agonists, GnRH antagonists were associated with fewer cardiovascular adverse event reports as monotherapy (adjusted reporting odds ratio [ROR]=0.70 [95% CI 0.59-0.84], p <0.001) and as combination therapy (ROR=0.47 [0.34-0.67], p <0.0001), driven by reductions in arterial vascular events. Second generation androgen receptor antagonists and abiraterone were associated with more reports of hypertension requiring hospitalization (ROR=1.21 [1.03-1.41], p=0.02 and ROR=1.19 [1.01-1.40], p=0.03, respectively), and more heart failure events when used in combination with GnRH antagonists (ROR=2.79 [1.30-6.01], p=0.009 and ROR=2.57 [1.12-5.86], p=0.03).
    Conclusions: In this retrospective analysis of a pharmacovigilance database, arterial vascular events were the most commonly reported cardiovascular adverse events in men on hormone therapy for prostate cancer. GnRH antagonists were associated with fewer reports of overall cardiovascular events and arterial vascular events than GnRH agonists. Additional study is needed to identify optimal strategies to reduce cardiovascular morbidity among men with prostate cancer receiving hormone therapy.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Androstenes/adverse effects ; Antineoplastic Agents, Hormonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cross-Sectional Studies ; Databases, Factual/statistics & numerical data ; Gonadotropin-Releasing Hormone/agonists ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Heart Failure/chemically induced ; Heart Failure/epidemiology ; Humans ; Hypertension/chemically induced ; Hypertension/epidemiology ; Male ; Middle Aged ; Pharmacovigilance ; Prostatic Neoplasms/drug therapy ; Retrospective Studies ; United States/epidemiology ; United States Food and Drug Administration/statistics & numerical data ; Young Adult
    Chemical Substances Androgen Antagonists ; Androstenes ; Antineoplastic Agents, Hormonal ; Gonadotropin-Releasing Hormone (33515-09-2) ; abiraterone (G819A456D0)
    Language English
    Publishing date 2021-04-19
    Publishing country United States
    Document type Journal Article ; Observational Study ; Research Support, N.I.H., Extramural
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000001785
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Retraction for Braden et al., "Distinct Action of the Retinoblastoma Pathway on the DNA Replication Machinery Defines Specific Roles for Cyclin-Dependent Kinase Complexes in Prereplication Complex Assembly and S-Phase Progression".

    Braden, Wesley A / Lenihan, Jon M / Lan, Zhengdao / Luce, K Scott / Zagorski, William / Bosco, Emily / Reed, Michael F / Cook, Jeanette G / Knudsen, Erik S

    Molecular and cellular biology

    2020  Volume 40, Issue 17

    Language English
    Publishing date 2020-08-14
    Publishing country United States
    Document type Journal Article ; Retraction of Publication
    ZDB-ID 779397-2
    ISSN 1098-5549 ; 0270-7306
    ISSN (online) 1098-5549
    ISSN 0270-7306
    DOI 10.1128/MCB.00319-20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study.

    Narayan, Hari K / Wei, Wei / Feng, Ziding / Lenihan, Daniel / Plappert, Ted / Englefield, Virginia / Fisch, Michael / Ky, Bonnie

    Open heart

    2017  Volume 4, Issue 1, Page(s) e000524

    Abstract: Background: Our objective was to determine the relevance of changes in myocardial mechanics in diagnosing and predicting cancer therapeutics-related cardiac dysfunction (CTRCD) in a community-based population treated with anthracyclines.: Methods: ... ...

    Abstract Background: Our objective was to determine the relevance of changes in myocardial mechanics in diagnosing and predicting cancer therapeutics-related cardiac dysfunction (CTRCD) in a community-based population treated with anthracyclines.
    Methods: Quantitative measures of cardiac mechanics were derived from 493 echocardiograms in 165 participants enrolled in the PREDICT study (A Multicenter Study in Patients Undergoing AnthRacycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment). Echocardiograms were obtained primarily at baseline (prior to anthracyclines), 6 and 12 months. Predictors included changes in strain; strain rate; indices of contractile function derived from the end-systolic pressure-volume relationship (end-systolic elastance (Ees
    Results: By 12 months, 31 participants developed CTRCD. Longitudinal and circumferential strain and strain rate, V
    Conclusions: Changes in non-invasively derived measures of myocardial mechanics are diagnostic and predictive of cardiac dysfunction with anthracycline chemotherapy in community populations. Our findings support the non-invasive assessment of measures of myocardial mechanics more broadly in clinical practice and emphasise the role of serial assessments of these measures during and after cardiotoxic cancer therapy.
    Trial registration number: NCT01032278; Pre-results.
    Language English
    Publishing date 2017-01-16
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2747269-3
    ISSN 2053-3624 ; 2044-6055
    ISSN 2053-3624 ; 2044-6055
    DOI 10.1136/openhrt-2016-000524
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: What's Next for Acute Heart Failure Research?

    Collins, Sean P / Levy, Phillip D / Fermann, Gregory J / Givertz, Michael M / Martindale, Jennifer M / Pang, Peter S / Storrow, Alan B / Diercks, Deborah D / Michael Felker, G / Fonarow, Gregg C / Lanfear, David J / Lenihan, Daniel J / Lindenfeld, JoAnn M / Frank Peacock, W / Sawyer, Douglas M / Teerlink, John R / Butler, Javed

    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine

    2017  Volume 25, Issue 1, Page(s) 85–93

    Abstract: Each year over one million patients with acute heart failure (AHF) present to a United States emergency department (ED). The vast majority are hospitalized for further management. The length of stay and high postdischarge event rate in this cohort have ... ...

    Abstract Each year over one million patients with acute heart failure (AHF) present to a United States emergency department (ED). The vast majority are hospitalized for further management. The length of stay and high postdischarge event rate in this cohort have changed little over the past decade. Therapeutic trials have failed to yield substantive improvement in postdischarge outcomes; subsequently, AHF care has changed little in the past 40 years. Prior research studies have been fragmented as either "inpatient" or "ED-based." Recognizing the challenges in identification and enrollment of ED patients with AHF, and the lack of robust evidence to guide management, an AHF clinical trials network was developed. This network has demonstrated, through organized collaboration between cardiology and emergency medicine, that many of the hurdles in AHF research can be overcome. The development of a network that supports the collaboration of acute care and HF researchers, combined with the availability of federally funded infrastructure, will facilitate more efficient conduct of both explanatory and pragmatic trials in AHF. Yet many important questions remain, and in this document our group of emergency medicine and cardiology investigators have identified four high-priority research areas.
    MeSH term(s) Acute Disease ; Disease Management ; Emergency Medicine/trends ; Heart Failure/therapy ; Humans ; Patient Discharge ; Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; Research/trends ; United States
    Language English
    Publishing date 2017-11-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1329813-6
    ISSN 1553-2712 ; 1069-6563
    ISSN (online) 1553-2712
    ISSN 1069-6563
    DOI 10.1111/acem.13331
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group.

    Collins, Sean P / Levy, Phillip D / Martindale, Jennifer L / Dunlap, Mark E / Storrow, Alan B / Pang, Peter S / Albert, Nancy M / Felker, G Michael / Fermann, Gregory J / Fonarow, Gregg C / Givertz, Michael M / Hollander, Judd E / Lanfear, David E / Lenihan, Daniel J / Lindenfeld, JoAnn M / Peacock, W Frank / Sawyer, Douglas B / Teerlink, John R / Butler, Javed

    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine

    2016  Volume 23, Issue 8, Page(s) 922–931

    Abstract: Management approaches for patients in the emergency department (ED) who present with acute heart failure (AHF) have largely focused on intravenous diuretics. Yet, the primary pathophysiologic derangement underlying AHF in many patients is not solely ... ...

    Abstract Management approaches for patients in the emergency department (ED) who present with acute heart failure (AHF) have largely focused on intravenous diuretics. Yet, the primary pathophysiologic derangement underlying AHF in many patients is not solely volume overload. Patients with hypertensive AHF (H-AHF) represent a clinical phenotype with distinct pathophysiologic mechanisms that result in elevated ventricular filling pressures. To optimize treatment response and minimize adverse events in this subgroup, we propose that clinical management be tailored to a conceptual model of disease that is based on these mechanisms. This consensus statement reviews the relevant pathophysiology, clinical characteristics, approach to therapy, and considerations for clinical trials in ED patients with H-AHF.
    MeSH term(s) Acute Disease ; Advisory Committees ; Aged ; Biomedical Research ; Consensus ; Diuretics ; Dose-Response Relationship, Drug ; Emergency Medicine/organization & administration ; Emergency Service, Hospital/organization & administration ; Female ; Heart Failure/drug therapy ; Heart Failure/etiology ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Male ; Societies, Medical
    Chemical Substances Diuretics
    Language English
    Publishing date 2016-08-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1329813-6
    ISSN 1553-2712 ; 1069-6563
    ISSN (online) 1553-2712
    ISSN 1069-6563
    DOI 10.1111/acem.13025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top